PRFX (PRFX) Stock Price & Analysis
PRFX (PRFX) fell 1.30% to USD 1.14 as of July 25, 2026 at 01:45 UTC, according to Nexqual real-time market data.
PRFX last closed at USD 1.15; the session ranged USD 1.1–1.19 on volume of 83,361 shares. Market capitalization is $3.45M, with a 52-week range of USD 1.1–17.95 (NCM). Source: Nexqual, July 25, 2026 at 01:45 UTC.
Key Statistics (as of July 25, 2026 at 01:45 UTC)
| Price | USD 1.14 |
|---|---|
| Change | ▼ 1.30% (down) |
| Previous Close | USD 1.15 |
| Open | USD 1.15 |
| Day Range | USD 1.1 – 1.19 |
| 52-Week Range | USD 1.1 – 17.95 |
| Volume | 83,361 shares |
| Market Cap | $3.45M |
| Exchange | NCM |
Technical Analysis (PRFX)
Nexqual's technical model rates PRFX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 01:45 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.57 (neutral) |
| vs SMA50 | Below (USD 1.51) |
| MACD | -0.12 (negative) |
Analyst Ratings (PRFX)
Wall Street analysts rate PRFX "None", per Nexqual as of July 25, 2026 at 01:45 UTC.
| Consensus Rating | None |
|---|
Earnings (PRFX)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-06-30 | USD -48 vs est -124.8 ▲ beat |
| 2024-03-31 | USD -326.4 vs est -288 ▼ miss |
Source: Nexqual, July 25, 2026 at 01:45 UTC.
Financials & Fundamentals (PRFX)
| Total Revenue | $17,000 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -16200.00% |
| Profit Margin | +0.00% |
| ROE | -90.37% |
| Debt / Equity | 0.23 |
| Current Ratio | 1.78 |
| Total Cash | $4.14M |
| Total Debt | $21,000 |
| Free Cash Flow | $-2.00M |
Source: Nexqual, July 25, 2026 at 01:45 UTC.
Financial Health Score (PRFX)
Nexqual rates PRFX's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 01:45 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $4M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$4M |
| Efficiency | Critical — ROE -90%, ROA -38.7% |
Ownership (PRFX)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.52% |
| Shares Outstanding | 3.04M |
| Float | 844,372 |
| Short % of Float | +4.20% |
Source: Nexqual, July 25, 2026 at 01:45 UTC.
Leadership (PRFX)
PRFX is led by Efraim Cohen-Arazi (age 70), Interim CEO & Director, per Nexqual as of July 25, 2026 at 01:45 UTC.
| Interim CEO & Director | Efraim Cohen-Arazi (age 70) |
|---|---|
| Executive Chairman | Ehud Geller |
| Chief Financial Officer | Eyal Broder (age 54) |
| Chief Operating Officer | Sigal Aviel eMBA (age 61) |
| Vice President of Pharmaceutical Operations | Rita Keynan M.Sc. (age 56) |
Major Backers & Investors (PRFX)
Notable institutional backers of PRFX include Citadel, according to Nexqual as of July 25, 2026 at 01:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Citadel | 0.43% |
Source: Nexqual, July 25, 2026 at 01:45 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AUUD | Auddia Inc. | USD 1.07 | ▼ 6.14% |
| BJDX | Bluejay Diagnostics, Inc. | USD 1.03 | ▼ 10.43% |
| SPRC | SciSparc Ltd. | USD 5.33 | ▲ 10.12% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.26 | ▼ 7.96% |
| RNAZ | TransCode Therapeutics, Inc. | USD 5.93 | ▼ 29.4% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:45 UTC. This page is informational and not investment advice.